- Home
- TILE vs SNDX Comparison
TILE vs SNDX Comparison
Compare TILE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- SNDX
- Stock Information
- Founded
- TILE 1973
- SNDX 2005
- Country
- TILE United States
- SNDX United States
- Employees
- TILE N/A
- SNDX N/A
- Industry
- TILE Home Furnishings
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- SNDX Health Care
- Exchange
- TILE Nasdaq
- SNDX Nasdaq
- Market Cap
- TILE 1.2B
- SNDX 1.1B
- IPO Year
- TILE N/A
- SNDX 2016
- Fundamental
- Price
- TILE $22.13
- SNDX $9.00
- Analyst Decision
- TILE Buy
- SNDX Strong Buy
- Analyst Count
- TILE 1
- SNDX 10
- Target Price
- TILE $30.00
- SNDX $35.80
- AVG Volume (30 Days)
- TILE 334.3K
- SNDX 1.8M
- Earning Date
- TILE 08-01-2025
- SNDX 07-31-2025
- Dividend Yield
- TILE 0.18%
- SNDX N/A
- EPS Growth
- TILE 44.62
- SNDX N/A
- EPS
- TILE 1.46
- SNDX N/A
- Revenue
- TILE $1,323,328,000.00
- SNDX $43,722,000.00
- Revenue This Year
- TILE $5.19
- SNDX $426.77
- Revenue Next Year
- TILE $4.91
- SNDX $98.31
- P/E Ratio
- TILE $15.17
- SNDX N/A
- Revenue Growth
- TILE 5.41
- SNDX N/A
- 52 Week Low
- TILE $14.13
- SNDX $8.58
- 52 Week High
- TILE $27.34
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- TILE 66.37
- SNDX 38.70
- Support Level
- TILE $20.74
- SNDX $8.77
- Resistance Level
- TILE $21.72
- SNDX $9.50
- Average True Range (ATR)
- TILE 0.56
- SNDX 0.53
- MACD
- TILE 0.13
- SNDX -0.04
- Stochastic Oscillator
- TILE 94.22
- SNDX 14.13
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.